281 related articles for article (PubMed ID: 15455280)
1. [Immunosuppressive therapy for inflammatory bowel disease: consensus by the Austrian working group on IBD].
Reinisch W; Dejaco C; Knoflach P; Petritsch W; Vogelsang H; Tilg H
Z Gastroenterol; 2004 Sep; 42(9):1033-45; discussion 1046-7. PubMed ID: 15455280
[TBL] [Abstract][Full Text] [Related]
2. Efficacy of immunosuppressive therapy for inflammatory bowel disease: a systematic review and meta-analysis.
Khan KJ; Dubinsky MC; Ford AC; Ullman TA; Talley NJ; Moayyedi P
Am J Gastroenterol; 2011 Apr; 106(4):630-42. PubMed ID: 21407186
[TBL] [Abstract][Full Text] [Related]
3. Immunosuppressive therapy in pediatric inflammatory bowel disease: results of a survey of the North American Society for Pediatric Gastroenterology and Nutrition. Subcommittee on Immunosuppressive Use of the Pediatric IBD Collaborative Research Forum.
Markowitz J; Grancher K; Mandel F; Daum F
Am J Gastroenterol; 1993 Jan; 88(1):44-8. PubMed ID: 8420272
[TBL] [Abstract][Full Text] [Related]
4. Monitoring 6-thioguanine nucleotide concentrations in Japanese children and adolescents with inflammatory bowel disease.
Ohtsuka Y; Arai K; Aoyagi Y; Fujii T; Yamakawa Y; Ohtani K; Ikuse T; Baba Y; Inage E; Kudo T; Suzuki R; Nagata S; Shimizu T
J Gastroenterol Hepatol; 2010 Oct; 25(10):1626-30. PubMed ID: 20880170
[TBL] [Abstract][Full Text] [Related]
5. Immunosuppressive drugs in the treatment of inflammatory bowel disease.
Aranda R; Horgan K
Semin Gastrointest Dis; 1998 Jan; 9(1):2-9. PubMed ID: 9547850
[TBL] [Abstract][Full Text] [Related]
6. Monitoring 6-thioguanine nucleotide concentrations in Japanese patients with inflammatory bowel disease.
Andoh A; Tsujikawa T; Ban H; Hashimoto T; Bamba S; Ogawa A; Sasaki M; Saito Y; Fujiyama Y
J Gastroenterol Hepatol; 2008 Sep; 23(9):1373-7. PubMed ID: 18662197
[TBL] [Abstract][Full Text] [Related]
7. [Inflammatory bowel disease--diagnosis and therapy].
Vogt W
Praxis (Bern 1994); 2005 Feb; 94(5):145-50. PubMed ID: 15745379
[TBL] [Abstract][Full Text] [Related]
8. Conventional therapy for moderate to severe inflammatory bowel disease: A systematic literature review.
Damião AOMC; de Azevedo MFC; Carlos AS; Wada MY; Silva TVM; Feitosa FC
World J Gastroenterol; 2019 Mar; 25(9):1142-1157. PubMed ID: 30863001
[TBL] [Abstract][Full Text] [Related]
9. IOIBD questionnaire on the clinical use of azathioprine, 6-mercaptopurine, cyclosporin A and methotrexate in the treatment of inflammatory bowel diseases.
Meuwissen SG; Ewe K; Gassull MA; Geboes K; Jewell D; Pallone F; Rachmilewitz D; Rask-Madsen J; Riddell BH; Sandborn BJ; Schmuck ML
Eur J Gastroenterol Hepatol; 2000 Jan; 12(1):13-8. PubMed ID: 10656204
[TBL] [Abstract][Full Text] [Related]
10. Efficacy of methotrexate in Crohn's disease and ulcerative colitis patients unresponsive or intolerant to azathioprine /mercaptopurine.
Wahed M; Louis-Auguste JR; Baxter LM; Limdi JK; McCartney SA; Lindsay JO; Bloom SL
Aliment Pharmacol Ther; 2009 Sep; 30(6):614-20. PubMed ID: 19552632
[TBL] [Abstract][Full Text] [Related]
11. [Chronic inflammatory bowel diseases].
Herrlinger K; Stange EF
Dtsch Med Wochenschr; 2004 Oct; 129(42):2241-50; quiz 2251-4. PubMed ID: 15529447
[No Abstract] [Full Text] [Related]
12. [The use of methotrexate in an inflammatory bowel diseases based on the review of the current literature].
Klimczak K; Łykowska-Szuber L; Krela-Kaźmierczak I; Eder P; Szymczak A; Stawczyk-Eder K; Linke K
Wiad Lek; 2016; 69(2 Pt 2):262-6. PubMed ID: 27487545
[TBL] [Abstract][Full Text] [Related]
13. Azathioprine: state of the art in inflammatory bowel disease.
Sandborn WJ
Scand J Gastroenterol Suppl; 1998; 225():92-9. PubMed ID: 9515759
[TBL] [Abstract][Full Text] [Related]
14. Immunosuppressive therapy of inflammatory bowel disease: a historical perspective.
Korelitz BI
Gastroenterologist; 1995 Jun; 3(2):141-52. PubMed ID: 7640945
[TBL] [Abstract][Full Text] [Related]
15. Refractory IBD: medical management.
Tremaine WJ
Neth J Med; 1997 Feb; 50(2):S12-4. PubMed ID: 9050327
[TBL] [Abstract][Full Text] [Related]
16. Appropriateness of immunosuppressive drugs in inflammatory bowel diseases assessed by RAND method: Italian Group for IBD (IG-IBD) position statement.
Caprilli R; Angelucci E; Cocco A; Viscido A; Annese V; Ardizzone S; Biancone L; Castiglione F; Cottone M; Meucci G; Paoluzi P; Papi C; Sturniolo GC; Vecchi M
Dig Liver Dis; 2005 Jun; 37(6):407-17. PubMed ID: 15893279
[TBL] [Abstract][Full Text] [Related]
17. [Ulcerative colitis. Chronic active course].
Dignass AU; Herrlinger K; Schölmerich J
Z Gastroenterol; 2004 Sep; 42(9):1006-10. PubMed ID: 15455274
[No Abstract] [Full Text] [Related]
18. Recent advances using immunomodulators for inflammatory bowel disease.
Nielsen OH; Bjerrum JT; Herfarth H; Rogler G
J Clin Pharmacol; 2013 Jun; 53(6):575-88. PubMed ID: 23408468
[TBL] [Abstract][Full Text] [Related]
19. Birth outcome in women with ulcerative colitis and Crohn's disease, and pharmacoepidemiological aspects of anti-inflammatory drug therapy.
Nørgård BM
Dan Med Bull; 2011 Dec; 58(12):B4360. PubMed ID: 22142578
[TBL] [Abstract][Full Text] [Related]
20. Combined use of cyclosporine and azathioprine or 6-mercaptopurine in pediatric inflammatory bowel disease.
Ramakrishna J; Langhans N; Calenda K; Grand RJ; Verhave M
J Pediatr Gastroenterol Nutr; 1996 Apr; 22(3):296-302. PubMed ID: 8708884
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
